Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Why Tryp Therapeutics is exploring the use of psilocybin to treat chronic pain

While several companies are exploring the use of psilocybin for depression, Tryp has decided to go a different route.

By Brian Buntz | July 21, 2021

Tryp TherapeuticsMany researchers are exploring the potential of the psychedelic compound psilocybin to treat conditions such as depression and post-traumatic stress disorder.

But psilocybin offers broader therapeutic promise as it appears to spur neuroplasticity, according to Greg McKee, CEO of Tryp Therapeutics (San Diego).

The company is exploring the use of psilocybin-based drugs for treating eating disorders and chronic pain.

“There’s a lot of similarities mechanistically in terms of how psilocybin works to treat depression that we think could apply to treating pain,” McKee said.

Tryp is working with researchers who believe psilocybin can support neuroplasticity in a manner that reduces chronic pain. Tryp’s research partners believe psilocybin can help correct abnormal neural firing in patients with chronic pain and related conditions.

Greg McKee

Greg McKee

If psilocybin promotes neuroplasticity in humans, as assumed, the compound could potentially treat conditions ranging from fibromyalgia to phantom limb pain to complex regional pain syndrome. “We think [psilocybin] applies to a lot of different areas in the chronic pain space,” McKee noted.

In terms of the current treatment landscape for chronic pain, many of the therapeutics in this area “have not shown lasting efficacy and patients drop off therapy, or there are challenging side effects,” McKee said.

The ongoing opioid crisis is another complication. Opioids played a significant role in fueling a record number of drug overdose deaths in 2020.

Tryp has research partnerships with the University of Florida and the University of Michigan. The company forged an alliance after discussing collaboration on fibromyalgia with Dr. Daniel Clauw, a professor of anesthesiology, medicine and psychiatry at the University of Michigan.

Clauw is an expert in fibromyalgia and chronic pain who has explored the potential of a range of drugs, including cannabinoids.

Tryp will collaborate with Dr. Dan Clauw, who leads the Chronic Pain & Fatigue Research Center and the Center for Consciousness Science at the University of Michigan, to explore novel methods of delivery of psilocybin and their impact on indices of pain as well as the role of psilocybin in inducing neurophysiological complexity and indices of pain.


Filed Under: clinical trials, Drug Discovery, Neurological Disease
Tagged With: chronic pain, depression, eating disorders, fibromyalgia, neuroplasticity, opioid, opioid abuse, opioids, phantom limb pain, psilocybin
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Human study tracks brain’s glymphatic flow in real time, opening Alzheimer’s drug avenues
An 8-year-old patient with gangliosidosis demonstrates improved mobility, walking unassisted on a soccer field after treatment with N-acetyl-L-leucine. (Still from video footage; parental consent obtained for use).
Modified amino acid approved for Niemann–Pick shows promise in early Parkinson’s research
AI-guided hunt points to PHGDH as an upstream drug target in Alzheimer’s disease
Why smaller, simpler molecular glues are gaining attention in drug discovery
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE